Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | PPOX | P50336 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639548 | 1.00 | CCR1 (0.47) | CCR1MAPTALDH1A1LMNASUV39H2 | |
| SCHEMBL12765552 | 0.91 | CCR1 (0.47) | CCR1MAPTALDH1A1LMNASUV39H2 | |
| SCHEMBL14724209 | 0.89 | CCR1 (0.45) | CCR1MAPTALDH1A1LMNASUV39H2 | |
| SCHEMBL13229276 | 0.88 | MAPT (0.44) | CCR1MAPTALDH1A1LMNAROCK2 | |
| SCHEMBL12726174 | 0.85 | MAPT (0.47) | MAPTALDH1A1LMNAROCK2PRKG1 | |
| SCHEMBL4811812 | 0.83 | CXCR3 (0.50) | CCR1MAPTALDH1A1LMNASUV39H2 | |
| SCHEMBL3071170 | 0.82 | MEN1 (0.47) | CCR1MAPTALDH1A1LMNAPPOX | |
| SCHEMBL3464357 | 0.81 | CCR1 (0.59) | CCR1 | |
| SCHEMBL3464356 | 0.81 | CCR1 (0.59) | CCR1 | |
| SCHEMBL13869125 | 0.81 | CCR1 (0.49) | CCR1SUV39H2ROCK2PRKG1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155203-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-09-06 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-1906965-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1931348-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1906965-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022257-A2 | MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2007002293-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885MAPT 4063/4885ALDH1A1 951/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885MAPT 4063/4885ALDH1A1 951/4885 |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 4546/4885ALDH1A1 864/4885 |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885MAPT 3597/4885ALDH1A1 1533/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | CCR1 1/4885MAPT 4063/4885ALDH1A1 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.